Expression of SATB2 in colon adenocarcinoma and its use for differential diagnosis

中华普通外科杂志 Pub Date : 2019-10-25 DOI:10.3760/CMA.J.ISSN.1007-631X.2019.10.020

Fangfang Liu, D. Shen, Z. Gao, Haiou Zhao, Chao Wang, Y. Ye, Yingteng Ma, F. Kong

{"title":"Expression of SATB2 in colon adenocarcinoma and its use for differential diagnosis","authors":"Fangfang Liu, D. Shen, Z. Gao, Haiou Zhao, Chao Wang, Y. Ye, Yingteng Ma, F. Kong","doi":"10.3760/CMA.J.ISSN.1007-631X.2019.10.020","DOIUrl":null,"url":null,"abstract":"Objectives \nTo study the significance of SATB2 expression in colon adenocarcinoma and its differential diagnosis function for ovarian metastatic adenocarcinoma. \n \n \nMethods \nImmunohistochemistry was used to detect the expression level of SATB2 in 130 cases of colon adenocarcinoma. The relationship between the positive rate of SATB2 expression in colon cancer and clinicopathological factors was studied. Forty-seven cases of pancreatic ductal adenocarcinoma, 22 cases of cholangiocarcinoma, 46 cases of gastric adenocarcinoma, and 53 cases of ovarian mucinous adenocarcinoma were studied respectively. \n \n \nResults \nThe positive expression rate of SATB2 in 130 cases of colon adenocarcinoma is 73.8%. The SATB2 expression bears no correlation with gender, age, tumor size, location, histology type, lymph node metastasis, staging, local recurrence, distant metastasis, survival, Kras mutation, and microsatellite stability. The expression rate of SATB2 is significantly higher in well differentiated and moderately differentiated colon adenocarcinoma than that in poorly differentiated adenocarcinoma (χ2=12.804, P=0.002); the expression rate in the cases without tumor deposit is significantly higher than in cases with tumor deposit (χ2=6.485, P=0.011). There was no positive expression in all cases of pancreatic adenocarcinoma, cholangiocarcinoma, gastric adenocarcinoma, nor in ovarian mucinous adenocarcinoma. \n \n \nConclusion \nThe expression of SATB2 is associated with the differentiation of colon adenocarcinoma and the formation of tumor deposit. SATB2 can be used as an effective tumor marker for identifying colorectal cancer ovarian metastases. \n \n \nKey words: \nColonic neoplasms; Neoplasm metastasis; Tumor marker","PeriodicalId":66425,"journal":{"name":"中华普通外科杂志","volume":"34 1","pages":"887-890"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华普通外科杂志","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1007-631X.2019.10.020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives To study the significance of SATB2 expression in colon adenocarcinoma and its differential diagnosis function for ovarian metastatic adenocarcinoma. Methods Immunohistochemistry was used to detect the expression level of SATB2 in 130 cases of colon adenocarcinoma. The relationship between the positive rate of SATB2 expression in colon cancer and clinicopathological factors was studied. Forty-seven cases of pancreatic ductal adenocarcinoma, 22 cases of cholangiocarcinoma, 46 cases of gastric adenocarcinoma, and 53 cases of ovarian mucinous adenocarcinoma were studied respectively. Results The positive expression rate of SATB2 in 130 cases of colon adenocarcinoma is 73.8%. The SATB2 expression bears no correlation with gender, age, tumor size, location, histology type, lymph node metastasis, staging, local recurrence, distant metastasis, survival, Kras mutation, and microsatellite stability. The expression rate of SATB2 is significantly higher in well differentiated and moderately differentiated colon adenocarcinoma than that in poorly differentiated adenocarcinoma (χ2=12.804, P=0.002); the expression rate in the cases without tumor deposit is significantly higher than in cases with tumor deposit (χ2=6.485, P=0.011). There was no positive expression in all cases of pancreatic adenocarcinoma, cholangiocarcinoma, gastric adenocarcinoma, nor in ovarian mucinous adenocarcinoma. Conclusion The expression of SATB2 is associated with the differentiation of colon adenocarcinoma and the formation of tumor deposit. SATB2 can be used as an effective tumor marker for identifying colorectal cancer ovarian metastases. Key words: Colonic neoplasms; Neoplasm metastasis; Tumor marker

查看原文本刊更多论文

SATB2在结肠腺癌中的表达及其鉴别诊断价值

目的探讨SATB2在结肠癌中的表达及其对卵巢转移性腺癌的鉴别诊断作用。方法应用免疫组织化学方法检测130例结肠癌组织中SATB2的表达水平。探讨了结肠癌SATB2表达阳性率与临床病理因素的关系。分别研究了47例胰腺导管腺癌、22例胆管癌、46例胃腺癌和53例卵巢粘液腺癌。结果SATB2在130例结肠癌中的阳性表达率为73.8%，与性别、年龄、肿瘤大小、部位、组织学类型、淋巴结转移、分期、局部复发、远处转移、生存率、Kras突变和微卫星稳定性无关。SATB2在高分化和中分化结肠癌中的表达率显著高于低分化腺癌（χ2=12.804，P=0.002）；胰腺癌、胆管癌、胃腺癌和卵巢粘液腺癌均无阳性表达（χ2=6.485，P=0.011）。结论SATB2的表达与结肠癌的分化和肿瘤沉积的形成有关。SATB2可作为一种有效的肿瘤标志物用于识别癌症卵巢转移。关键词：结肠肿瘤；肿瘤转移；肿瘤标志物

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中华普通外科杂志

自引率

0.00%

发文量

9825